The EPHESUS trial aimed to determine whether the pentasaccharide fondaparinux was more effective than low-molecular-weight heparin at preventing deep venous thrombosis after elective hip replacement.
The multi-centre, double-blind trial enrolled 2309 consecutive patients, aged over 18 years, undergoing elective hip-replacement surgery. Patients were allocated to postoperative 2.5 mg s/c injections of fondaparinux vs. 40 mg s/c injections of enoxaparin daily.
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page